Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy


Autoři: Marina Picillo aff001;  Sofia Cuoco aff001;  Immacolata Carotenuto aff001;  Filomena Abate aff001;  Roberto Erro aff001;  Giampiero Volpe aff001;  Maria Teresa Pellecchia aff001;  Eleonora Catricalà aff002;  Stefano Cappa aff002;  Paolo Barone aff001
Působiště autorů: Center for Neurodegenerative diseases (CEMAND), Department of Medicine, Surgery and Dentistry, Neuroscience section, University of Salerno, Salerno, Italy aff001;  University School for Advanced Studies IUSS Pavia, Pavia, Italy aff002;  IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy aff003
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223621

Souhrn

Background

Progressive Supranuclear Palsy (PSP) patients present language disturbances in tasks like naming, repetition, reading, word comprehension and semantic association compared to Parkinson’s disease (PD) and healthy controls (HC).

Objective

In the present study we sought to validate a Screening for Aphasia in NeuroDegeneration (SAND) battery version specifically tailored on PSP patients and to describe language impairment in relation to PSP disease phenotype and cognitive status.

Methods and results

Fifty-one PSP [23 with Richardson’s syndrome (PSP-RS), 10 with predominant parkinsonism (PSP-P) and 18 with the other variant syndromes of PSP (vPSP)], 28 PD and 30 HC were enrolled in the present study. By excluding the tasks with poor acceptability (i.e., writing and picture description tasks) and increasing the items related to the remaining tasks, we showed that the PSP-tailored SAND Global Score is an acceptable, consistent and reliable tool to screen language disturbances in PSP. However, we failed to detect major differences in language involvement according to disease phenotype. Differently, we showed that patients with dementia present worse language performances.

Conclusions

Taking into account specific disease features, the combination of the SAND subscores included in the PSP-tailored SAND better represents language abilities in PSP. Furthermore, we showed that language disturbances feature PSP patients irrespective of disease phenotype, but parallels the deterioration of the global cognitive function.

Klíčová slova:

Behavior – Cognitive impairment – Dementia – Diagnostic medicine – Language – Parkinson disease – Semantics – Sentence processing


Zdroje

1. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU, Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches, Lancet Neurol 2017;16(7):552–563. doi: 10.1016/S1474-4422(17)30157-6 28653647

2. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al, Movement Disorder Society-endorsed PSP Study Group, Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32(6):853–864. doi: 10.1002/mds.26987 28467028

3. Burrell JR, Ballard KJ, Halliday GM, Hodges JR, Aphasia in Progressive Supranuclear Palsy: As Severe as Progressive Non-Fluent Aphasia. Journal of Alzheimer's Disease, 2018;61(2):705–715 doi: 10.3233/JAD-170743 29254097

4. Catricalà E, Boschi V, Cuoco S, Galiano F, Picillo M, Gobbi E, et al. The language profile of progressive supranuclear palsy, Cortex 2019;115:294–308. doi: 10.1016/j.cortex.2019.02.013 30884283

5. Battista P, Catricalà E, Piccininni M, Copetti M, Esposito V, Polito C, et al, Screening for Aphasia in NeuroDegeneration for the Diagnosis of Patients with Primary Progressive Aphasia: Clinical Validity and Psychometric Properties. Dementia and Geriatric Cognitive Disorders, 2018;46:243–252. doi: 10.1159/000492632 30352431

6. Catricalà E, Gobbi E, Battista P, Miozzo A, Polito C, Boschi V, et al, SAND: a Screening for Aphasia in NeuroDegeneration. Development and normative data. Neurological Sciences, 2017;38(8):1469–1483. doi: 10.1007/s10072-017-3001-y 28578483

7. Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P, MDS PSP Criteria in Real-Life Clinical Setting: Motor and Cognitive Characterization of Subtypes, Mov disord 2017;33(8):1361–1365.

8. Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, et al; Movement Disorder Society-endorsed PSP Study Group. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord Epub 2019 Mar 18.

9. Golbe LI, Ohman-Strickland PA, A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552–1565. doi: 10.1093/brain/awm032 17405767

10. Santangelo G, Cuoco S, Pellecchia MT, Erro R, Barone P, Picillo M, Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy, J Neurol 2018;265(11):2602–2613. doi: 10.1007/s00415-018-9038-x 30178175

11. Kjaergaard M, Arfwedson W, Waterloo K, Jorde R, A study of the psychometric properties of the Beck Depression Inventory-II, the Montgomery and Åsberg Depression Rating Scale, and the Hospital Anxiety and Depression Scale in a sample from a healthy population, Scand J Psychol 2014;55(1):83–89. doi: 10.1111/sjop.12090 24256317

12. Santangelo G, Barone P, Cuoco S, Raimo S, Pezzella D, Picillo M, Vitale C, Apathy in untreated, de novo patients with Parkinson‘s disease: Validation study of apathy evaluation scale, J Neurol 2014;261:2319–2328. doi: 10.1007/s00415-014-7498-1 25228003

13. Picillo M, Cuoco S, Tepedino MF, Cappiello A, Volpe G, Erro R, et al, Motor, cognitive and behavioral differences in MDS PSP phenotypes. Journal of Neurology 2019 Apr 15 Epub ahead of print

14. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov disord 2012;27(3):349–356. doi: 10.1002/mds.24893 22275317

15. Acquadro C, Joyce CRB, Patrick DL, Ware JE, Wu AW, Scientific Advisory Committee (2004) Linguistic validation manual for patient reported outcomes (PRO) instruments. MAPI Research Institute

16. Cronbach LJ, Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297–334.

17. Scientific Advisory Committee of the Medical Outcomes Trust, Assessing health status and quality-of-life instruments:attributes and review criteria. Qual Life Res 2002;11:193–205. 12074258

18. Nunnally JC, IH Bernstein, Psychometric theory. McGraw-Hill, New York (1994)

19. Catricalá E, Della Rosa PA, Ginex V, Mussetti Z Plebani V, Cappa SF. An Italian battery for the assessment of semantic memory disorders. Neurol Sci 2013;34(6):985–993 doi: 10.1007/s10072-012-1181-z 22960873


Článek vyšel v časopise

PLOS One


2019 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se